WSD4000
Impaired sexual response and function in women
Discovery/FeasibilityEarly Feasibility Study planned for 2025
Key Facts
Indication
Impaired sexual response and function in women
Phase
Discovery/Feasibility
Status
Early Feasibility Study planned for 2025
Company
About Futura Medical
Futura Medical has successfully transitioned from an R&D entity to a revenue-generating commercial company with the global launch of Eroxon®, its flagship OTC treatment for erectile dysfunction. Its strategy centers on developing clinically proven, topical sexual health products and commercializing them through de-risked partnerships with major consumer healthcare players like Haleon and Cooper. With a lean, semi-virtual structure and a clear pipeline, Futura aims to capitalize on the large, underserved OTC sexual health market driven by demographic trends and growing consumer self-care demand.
View full company profile